Prasugrel
- Generic Name
- Prasugrel
- Brand Names
- Effient, Efient, Prasugrel Viatris (previously Prasugrel Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H20FNO3S
- CAS Number
- 150322-43-3
- Unique Ingredient Identifier
- 34K66TBT99
- Background
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.
- Indication
用于心力衰竭、卒中、不稳定心绞痛等心脑血管疾病以及有急性冠状动脉综合征需要进行经皮冠脉介入术的患者。
- Associated Conditions
- Cardiovascular Events
Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry
- Conditions
- Platelet InhibitionCoronary Stent Implantation
- Interventions
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Kaiser Franz Josef Hospital
- Target Recruit Count
- 1008
- Registration Number
- NCT01515345
- Locations
- 🇦🇹
Kaiser Franz Josef Hospital, Vienna, Austria
Rapid Activity of Platelet Inhibitor Drugs Study
- Conditions
- ST-segment Elevation Myocardial Infarction
- Interventions
- First Posted Date
- 2012-01-13
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Careggi Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT01510171
- Locations
- 🇮🇹
Careggi Hospital, Florence, Italy
Impact of Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients With High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention
- First Posted Date
- 2012-01-09
- Last Posted Date
- 2012-05-23
- Lead Sponsor
- Assistance Publique Hopitaux De Marseille
- Target Recruit Count
- 187
- Registration Number
- NCT01505790
- Locations
- 🇫🇷
Assistance Publique Hopitaux de Marseille, Marseille, France
Prasugrel Versus Clopidogrel to TREAT High Platelet Reactivity
- Conditions
- Acute Coronary Syndrome
- Interventions
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2014-10-08
- Lead Sponsor
- University of Pecs
- Target Recruit Count
- 147
- Registration Number
- NCT01493999
- Locations
- 🇭🇺
University of Pécs, Heart Institute, Pécs, Hungary
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 33
- Registration Number
- NCT01476696
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pittsburgh, Pennsylvania, United States
Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial
- First Posted Date
- 2011-11-06
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- Gennaro Sardella
- Target Recruit Count
- 30
- Registration Number
- NCT01465828
- Locations
- 🇮🇹
Dept.of Cardiovascular Sciences,Policlinico Umberto I, Rome, Italy
Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)
- First Posted Date
- 2011-11-01
- Last Posted Date
- 2012-07-11
- Lead Sponsor
- University of Patras
- Target Recruit Count
- 27
- Registration Number
- NCT01463150
- Locations
- 🇬🇷
Cardiology Department Patras University Hospital, Rio, Achaia, Greece
Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
- First Posted Date
- 2011-11-01
- Last Posted Date
- 2012-04-10
- Lead Sponsor
- University of Patras
- Target Recruit Count
- 50
- Registration Number
- NCT01463163
- Locations
- 🇬🇷
Cardiology Department Patras University Hospital, Rio, Achaia, Greece
Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Deutsches Herzzentrum Muenchen
- Target Recruit Count
- 70
- Registration Number
- NCT01456364
- Locations
- 🇩🇪
Deutsches Herzzentrum, München, Bavaria, Germany
🇩🇪Klinikum der Ludwig-Maximilians-Universität München, München, Bavaria, Germany
🇭🇺Heart Center Balatonfüred, Dept. of Cardiology, Balatonfüred, Hungary
Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)
- First Posted Date
- 2011-10-14
- Last Posted Date
- 2013-04-25
- Lead Sponsor
- Ottawa Heart Institute Research Corporation
- Target Recruit Count
- 102
- Registration Number
- NCT01452139
- Locations
- 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.